Parkinson's Disease Drug Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2027

The global Parkinson's disease drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Parkinson's disease (PD) is a disorder of the central nervous system. It is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination. Additionally, levodopa controls the symptoms of the condition, particularly slow movements and stiff, rigid body parts and is the most commonly prescribed medicine for PD. The major factor for the growth of the market during the forecast period is the increasing prevalence of Parkinson's disease across the globe.

According to the Parkinson Foundation, almost one million people are living with PD in the US which is expected to rise to 1.2 million in 2030. Additionally, approximately 60,000 Americans are diagnosed with PD each year and more than 10 million people are living with PD globally. Further, Parkinson disease increases with age, however, an estimated 4% of people with PD are diagnosed before age 50. Moreover, the prevalence of PD in men are 1.5 times as compared to women. Hence, the increasing prevalence of this disease is in turn driving the growth of the global Parkinson's disease drug market.

To Request a Sample of our Report on Parkinson's Disease Drug Market: https://www.omrglobal.com/request-sample/parkinsons-disease-drug-market-overview

Some major players in the market include AbbVie Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co. Inc., and Teva Pharmaceuticals Industries Ltd. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2021, Optimus Pharma declared that it has received DCGI approval for its Anti-Parkinson's drug Safinamide. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Mechanism of Action

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- AbbVie Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Merck & Co. Inc., and Teva Pharmaceuticals Industries Ltd.



(Get 15% Discount on Buying this Report)

A full Report of Parkinson's Disease Drug Market is Available @ https://www.omrglobal.com/industry-reports/parkinsons-disease-drug-market-overview

Global Parkinson's Disease Drug Market Report by Segment

By Action

• Dopamine Agonists

• Anticholinergic

• MAO-B inhibitors

• Amantadine

• Carbidopa-levodopa

• COMT Inhibitors

• Others

Global Parkinson's Disease Drug Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.